Basic pharmacology of botulinum toxin in the lower urinary tract

Tzu Chi Medical Journal

Volumn 19, Issue 3, 2007, Pages 109-114

  Lin, Alex Tong Long ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Botulinum toxin; Pharmacology; Prostate; Urethra; Urinary bladder

Indexed keywords

ACETYLCHOLINE; ADENOSINE TRIPHOSPHATE; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CALCITONIN GENE RELATED PEPTIDE; CYCLOPHOSPHAMIDE; NEUROPEPTIDE Y; NITRIC OXIDE; NORADRENALIN; POLYPEPTIDE; PROTEINASE; SNARE PROTEIN; SUBSTANCE P; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; TETANUS TOXIN;

BLADDER; CHOLINERGIC NERVE; CONSTIPATION; DENERVATION; DRUG FORMULATION; DRUG MECHANISM; DYSPHAGIA; DYSTONIA; ENZYME ACTIVITY; EXOCRINE GLAND; EXOCRINE SECRETION; EXOCYTOSIS; GALLBLADDER DISEASE; GENE FUNCTION; HEAVY CHAIN; HORMONE RELEASE; HUMAN; INFLAMMATION; LIGHT CHAIN; MEMBRANE REACTOR; MUSCLE ATROPHY; MUSCLE WEAKNESS; NEUROMUSCULAR SYNAPSE; NEUROTRANSMITTER RELEASE; NOCICEPTION; NONHUMAN; PAIN; PROTEIN DEGRADATION; PTOSIS; REVIEW; SKELETAL MUSCLE; SMOOTH MUSCLE; SMOOTH MUSCLE CONTRACTION; SPASTICITY; TREATMENT CONTRAINDICATION; URETHRA; UROTHELIUM; XEROSTOMIA;

EID: 35348940815     PISSN: 10163190     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1016-3190(10)60002-X     Document Type: Review

References (47)

1. Bonifacino JS, Glick BS. The mechanisms of vesicle budding and fusion. Cell 2004;116:153-66.
2. Hong W. SNAREs and traffic. Biochim Biophys Acta 2005;1744:493-517.
3. Dong M, Yeh F, Tepp WH, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006;312:592-6.
4. Harper M, Fowler CJ, Dasgupta P. Botulinum toxin and its applications in the lower urinary tract. BJU Int 2004;93:702-6.
5. Smith CP, Chancellor MB. Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol 2004;171:2128-37.
6. Ellies M, Laskawi R, Gotz W, et al. Immunohistochemical and morphometric investigations of the influence of botulinum toxin on the submandibular gland of the rat. Eur Arch Otorhinolaryngol 1999;256:148-52.
7. Smith CP, Franks ME, McNeil BK, et al. Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 2003;169:1896-900.
8. Wonnacott S. Inhibition by botulinum toxin of acetylcholine release from synaptosomes: latency of action and the role of gangliosides. J Neurochem 1980;34:1567-73.
9. Shone CC, Melling J. Inhibition of calcium-dependent release of noradrenaline from PC12 cells by botulinum type-A neurotoxin. Long-term effects of the neurotoxin on intact cells. Eur J Biochem 1992;207:1009-16.
10. Ashton AC, Dolly JO. Characterization of the inhibitory action of botulinum neurotoxin type A on the release of several transmitters from rat cerebrocortical synaptosomes. J Neurochem 1988;50:1808-16.
11. Morris JL, Jobling P, Gibbins IL. Botulinum neurotoxin A attenuates release of norepinephrine but not NPY from vasoconstrictor neurons. Am J Physiol heart Circ Physiol 2002;283:H2627-35.
12. Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004;44:35-42.
13. Chuang YC, Yoshimura N, Huang CC, et al. Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol 2004;172:1529-32.
14. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000;38:245-58.
15. Smith CP, Vemulakonda VM, Kiss S, et al. Enhanced ATP release from rat bladder urothelium during chronic bladder inflammation: effect of botulinum toxin A. Neurochem Int 2005;47:291-7.
16. Wang EC, Lee JM, Ruiz WG, et al. ATP and purinergic receptor-dependent membrane traffic in bladder umbrella cells. J Clin Invest 2005;115:2412-22.
17. Morris JL, Jobling P, Gibbins IL. Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons. Am J Physiol Heart Circ Physiol 2001;281:H2124-32.
18. Olgart C, Gustafsson LE, Wiklund NP. Evidence for non-vesicular nitric oxide release evoked by nerve activation. Eur J Neurosci 2000;12:1303-9.
19. James AN, Ryan JP, Parkman HP. Inhibitory effects of botulinum toxin on pyloric and antral smooth muscle. Am J Physiol Gastrointest Liver Physiol 2003;285:G291-7.
20. Hassan SM, Jennekens FG, Veldman H. Botulinum toxin-induced myopathy in the rat. Brain 1995;118(Pt 2):533-45.
21. Ma J, Shen J, Lee CA, et al. Gene expression of nAChR, SNAP-25 and GAP-43 in skeletal muscles following botulinum toxin A injection: a study in rats. J Orthop Res 2005;23:302-9.
22. Chuang YC, Huang CC, Kang HY, et al. Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland. J Urol 2006;175:1158-63.
23. Liu Z, Tearle AW, Nai Q, et al. Rapid activity-driven SNARE-dependent trafficking of nicotinic receptors on somatic spines. J Neurosci 2005;25:1159-68.
24. Jain S, Tamer SK, Hiran S. Botulinum toxin as therapeutic agent in local hyperhydrosis. J Assoc Physicians India 2002;50:273-4.
25. Swartling C, Naver H, Lindberg M. Botulinum A toxin improves life quality in severe primary focal hyperhidrosis. Eur J Neurol 2001;8:247-52.
26. Naumann M, Hofmann U, Bergmann I, et al. Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. Arch Dermatol 1998;134:301-4.
27. Jongerius PH, Joosten F, Hoogen FJ, et al. The treatment of drooling by ultrasound-guided intraglandular injections of botulinum toxin type A into the salivary glands. Laryngoscope 2003;113:107-11.
28. Porta M, Gamba M, Bertacchi G, et al. Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders. J Neurol Neurosurg Psychiatry 2001;70:538-40.
29. Nadelhaft I. Cholinergic axons in the rat prostate and neurons in the pelvic ganglion. Brain Res 2003;989:52-7.
30. Dixon JS, Jen PY, Gosling JA. The distribution of vesicular acetylcholine transporter in the human male genitourinary organs and its co-localization with neuropeptide Y and nitric oxide synthase. Neurourol Urodyn 2000;19:185-94.
31. Doggweiler R, Zermann DH, Ishigooka M, et al. Botox-induced prostatic involution. Prostate 1998;37:44-50.
32. Cui M, Khanijou S, Rubino J, et al. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004,107:125-33.
33. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005;26:785-93.
34. Chuang YC. Intraprostatic capsaicin injection as a novel model for non-bacteria prostatitis. J Urol 2006. (Abstract)
35. Scott AB, Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord 1988;3:333-5.
36. Herrero BA, Ecklung AE, Streett CS, et al. Experimental botulism in monkeys - a clinical pathological study. Exp Mol Pathol 1967;6:84-95.
37. Bakheit AM, Ward CD, McLellan DL. Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: a report of two cases. J Neurol Neurosurg Psychiatry 1997;62:198.
38. Bhatia KP, Munchau A, Thompson PD, et al. Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases. J Neurol Neurosurg Psychiatry 1999;67:90-3.
39. Wyndaele JJ, Van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord 2002;40:599-600.
40. Wilson F. Botulinum toxin-A risks overcome by proper technique. Cosmetic Surg Times 2001;12.
41. Claus D, Druschky A, Erbguth F. Botulinum toxin: influence on respiratory heart rate variation. Mov Disord 1995;10:574-9.
42. Nebe A, Schelosky L, Wissel J, et al. No effects on heart-rate variability and cardiovascular reflex tests after botulinum toxin treatment of cervical dystonia. Mov Disord 1996;11:337-9.
43. Schnider P, Brichta A, Schmied M, et al. Gallbladder dysfunction induced by botulinum A toxin. Lancet 1993;342:811-2.
44. Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 2003;49:34-8.
45. Dykstra DD, Sidi AA. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil 1990;71:24-6.
46. Ghei M, Maraj BH, Miller R, et al. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol 2005;174:1873-7.
47. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nene 1997;(Suppl 6):S146-68.